ASH Registry will advance state of care for blood cancers and other hematologic diseases
NEW HAVEN — The American Society of Hematology (ASH) has announced their selection of Prometheus Research to build and support ASH Registry, a comprehensive data registry infrastructure capable of facilitating scientific research across the broad spectrum of blood diseases. The solution will demonstrably advance ASH’s mission of helping hematologists conquer blood diseases worldwide. The Society aims to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.
With more than 17,000 members from nearly 100 countries, ASH is the world’s largest professional society serving both clinicians and scientists who are working to conquer blood diseases. The ASH Registry will leverage Prometheus’ RexRegistry technology—the industry’s only “open core,” research-grade clinical data registry platform—and nearly 20 years of clinical research informatics expertise.
“We chose Prometheus Research based on their unique approach and their track record of building world-class health registries. They have both the software and the expertise to empower ASH’s vision of a transformative data infrastructure capable of repeatedly delivering meaningful improvements in the lives of patients and families affected by blood diseases,” said Melissa Francisco, MBA, Director of ASH Registry.
The Prometheus registry approach is predicated on delivering scalable methods and technologies that are responsive to evolving industry data standards and uses while preserving data fitness and reusability. Its RexRegistry platform employs both legacy and state-of-the-art data acquisition pathways, and can dynamically transform registry data into the information model best suited to address new questions and analyses.
“Prometheus is the ideal informatics partner for the ASH Registry,” said Leon Rozenblit, JD, Ph.D., Founder and CEO of Prometheus, “and we are optimistic about the progress that will come from our working together to conquer rare blood disorders, including hematologic malignancies.”
About Prometheus Research
Prometheus Research (www.prometheusresearch.com) is the principal informatics partner to organizations engaged in ambitious translational research endeavors and national quality-improvement initiatives. Our research-grade clinical registry solutions leverage open technologies and standards to deliver unparalleled versatility when acquiring data and exceptional quality when analyzing and repurposing data. Together with our consulting and analysis services, Prometheus helps forward-thinking health institutions build data assets today that will advance the state of care for future generations.
About the American Society of Hematology
The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.
If you would like more information on this topic, please contact Rosemarie Gallichio at (203) 672-5845 or email firstname.lastname@example.org.